Sarcoidosis future or investigational therapies: Difference between revisions
Created page with "__NOTOC__ {{Sarcoidosis}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{Reflist|..." |
No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Sarcoidosis}} | {{Sarcoidosis}} | ||
{{CMG}} {{AE}}Roshan Dinparasti Saleh M.D. | |||
==Overview== | |||
The emergence of biological therapies has increased the therapeutic options available to treat [[sarcoidosis]], with monoclonal anti-TNF agents being the most promising, but their use is still limited by a lack of licensing and costs. | |||
==Future or investigational therapies== | |||
The emergence of biological therapies has increased the therapeutic options available to treat [[sarcoidosis]], with monoclonal anti-TNF agents being the most promising, but their use is still limited by a lack of licensing and costs. | |||
==References== | ==References== | ||
{{Reflist|2}} | |||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 23:24, 14 May 2018
|
Sarcoidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Sarcoidosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Sarcoidosis future or investigational therapies |
|
Risk calculators and risk factors for Sarcoidosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Roshan Dinparasti Saleh M.D.
Overview
The emergence of biological therapies has increased the therapeutic options available to treat sarcoidosis, with monoclonal anti-TNF agents being the most promising, but their use is still limited by a lack of licensing and costs.
Future or investigational therapies
The emergence of biological therapies has increased the therapeutic options available to treat sarcoidosis, with monoclonal anti-TNF agents being the most promising, but their use is still limited by a lack of licensing and costs.